Benzinga | Dec 5, 2021 06:43PM EST

Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it will host an investor conference call and webcast tomorrow morning to discuss the topline results from the PEACE Phase 3 clinical trial of pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D).

Investors and the public are invited to listen to a live audio webcast of the conference call on December 6, 2021, at 8:00am ET, which can be accessed prior to the start of the call by dialing 1-877-425-9470 (U.S.) or 1-201-389-0878 (International) Conference ID 13725511 or through the Events & Presentations section of the Company's website.